Global Lewy Body Dementia Size 2025, Forecast To 2034
26 Mar, 2025
What Has Been The Evolution of the Lewy Body Dementia Market in Recent Years?
The lewy body dementia market has seen considerable growth due to a variety of factors.
• The market for Lewy body dementia has significantly expanded over the recent past. Its growth is projected to increase from $1.12 billion in 2024 to $1.21 billion in 2025, presenting a compound annual growth rate (CAGR) of 7.5%.
Factors contributing to this growth in the historical period include an upsurge in the aging populace, heightened awareness regarding neurodegenerative ailments, an increase in healthcare spending, enhanced diagnostic requirements and the sanctioning of dementia medications by regulatory bodies.
What Are the Future Growth Projections for the Lewy Body Dementia Market?
The lewy body dementia market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations indicate that the market size for lewy body dementia will experience robust growth in the coming years. The market is projected to reach a value of $1.60 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.2%.
Factors such as increased instances of dementia, more investment in R&D, a surge in demand for early detection, broadening of telemedicine usage, and a shift towards personalized medical care can all be attributed to this expected growth. Significant trends during the forecast period include the advent of targeted treatment methods, an increase in clinical trials, advancements in diagnostic methods, technological progress, and a focus on innovative therapeutic approaches.
What Are The Core Factors Supporting Growth In The Lewy Body Dementia Market?
The anticipated escalation in occurrences of conditions related to the brain is set to stimulate the expansion of the lewy body dementia market. Brain-related disorders encompass a variety of ailments which can affect the brain’s continuity and functionality, often triggering cognitive impairment, loss of memory and behavioral fluctuations. Aging, hereditable tendencies and environmental elements contribute to the escalating prevalence of such brain-related conditions. Consequently, the rising incidences of these disorders catalyze the need for superior treatments and early diagnosis of lewy body dementia. This further fuels research, fund allocation and the creation of modern, effective solutions, accelerating progress in the identification and treatment of LBD. For example, in October 2023, the World Federation of Neurology, a UK-based conglomerate of national neurological societies, reported over 40% of the global populace was suffering from neurological conditions. This figure is anticipated to nearly double by 2050. Consequently, this escalating prevalence of conditions linked to the brain will stimulate the expansion of the lewy body dementia market.
What Are The Major Segments Within The Global Lewy Body Dementia Market?
The lewy body dementia market covered in this report is segmented –
1) By Diagnosis: Clinical Diagnosis, Biomarker-Based Diagnosis
2) By Medication: Cholinesterase Inhibitors, Antipsychotics, Antidepressants, Other Medications
3) By End-User: Hospitals, Specialty Clinics, Long-Term Care Facilities, Other End-Users
Subsegments:
1) By Clinical Diagnosis: Neuropsychological Testing, Neurological Examination, Medical History Review, Cognitive Function Assessment
2) By Biomarker-Based Diagnosis: Cerebrospinal Fluid (CSF) Biomarkers, Imaging Biomarkers (PET, MRI), Genetic Biomarkers, Blood-Based Biomarkers
What New Trends Are Influencing The Lewy Body Dementia Market?
Key players in the lewy body dementia market are dedicating resources to research with the aim of bettering neurodegenerative treatments. The inputs for these researches comprise funds, time, and concerted efforts targeted towards the pursuit of technological and scientific studies. These investigations are designed to bring new understanding, conceive advanced solutions, or elevate existing methods. They aid in the scrutiny of diseases and the synthesis of new medicines, all aiming at enhancing patient outcomes. For instance, in March 2023, the National Institute on Aging, an agency of the US government, allocated $21 million for the progression of drug development research concerning Lewy Body Dementia (LBD). Researchers from the University of Miami Miller School of Medicine have embarked on a Phase 2b study of neflamapimod after receiving promising preliminary results.
Who Are the Key Players In The Lewy Body Dementia Market?
Major companies operating in the lewy body dementia market are:
• Eli Lilly and Company
• Mayo Foundation for Medical Education and Research
• Eisai Co. Ltd.
• Sumitomo Dainippon Pharma Co. Ltd.
• Georgetown University Medical Center
• Alzheimer's Society
• BioArctic AB
• Annovis Bio Inc.
• Sun Pharma Advanced Research Company Limited
• Voyager Therapeutics Inc.
• Cognition Therapeutics
• Athira Pharma
• Allergan plc
• Inhibikase Therapeutics
• CuraSen Therapeutics Inc.
• CervoMed Inc.
• AC Immune SA
• ProMIS Neurosciences Inc.
• Aptinyx Inc.
• EIP Pharma Inc.
What Is The Most Dominant Region In The Lewy Body Dementia Market?
North America was the largest region in the lewy body dementia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lewy body dementia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.